吕汪霞,袁梅琴,史 钟.阿帕替尼治疗晚期难治性软组织肉瘤28例的疗效和安全性[J].肿瘤学杂志,2018,24(6):592-596. |
阿帕替尼治疗晚期难治性软组织肉瘤28例的疗效和安全性 |
Efficacy and Safety of Apatinib in the Treatment of 28 Patients with Advanced Refractory Soft Tissue Sarcomas |
投稿时间:2018-03-07 |
DOI:10.11735/j.issn.1671-170X.2018.06.B012 |
|
|
中文关键词: 阿帕替尼 软组织肉瘤 疗效 不良反应 |
英文关键词:apatinib soft tissue sarcomas efficacy safety |
基金项目: |
|
摘要点击次数: 2491 |
全文下载次数: 601 |
中文摘要: |
摘 要:[目的] 评价阿帕替尼治疗晚期难治性软组织肉瘤疗效及不良反应。[方法] 2015年5月至2017年5月晚期难治性软组织肉瘤28例患者口服阿帕替尼500mg,每日1次,28d为1个疗程,直至疾病进展或无法耐受的毒副反应。采用RECISIT1.1评价疗效,CTCAE4.03评价不良反应。[结果] 28例患者中,PR 6例(21.4%),SD 17例(60.7%),PD 5例(17.9%),ORR为24.1%,DCR为82.1%。患者的中位生存期为3.7个月(95%CI:2.9~4.4),中位总生存期为9.1个月(95%CI:7.3~11.0)。3~4级不良反应较多的血液学毒性为白细胞减少和中性粒细胞减少,发生率均为10.7%,非血液学毒性为手足综合征(14.2%)、高血压(7.1%)和蛋白尿(7.1%)。[结论] 阿帕替尼治疗晚期难治性软组织肉瘤体现出一定的疗效,且不良反应可耐受。 |
英文摘要: |
Abstract:[Objective] To evaluate the efficacy and safety of apatinib in patients with advanced refractory soft tissue sarcomas. [Methods] Between May 2015 to May 2017,twenty-eight patients were enrolled. Patients received apatinib500mg once daily in a 28-day cycle. Response was assessed using RECIST 1.1 criteria. Toxicity was recorded using CTCAE version 4.03. [Results] Of 28 patients,6 patient had PR(21.4%),17 patients had SD (60.7%) and 5 had PD(17.9%). The ORR was 24.1% and DCR was 82.1%. The median PFS was 3.7 months(95%CI:2.9~4.4). T he median OS was 9.1months (95%CI:7.3~11.0). The grade3/4 toxicities were leukopenia(10.7%),neutropenia(10.7%),hand-foot syndrome (14.2%),hypertension (7.1%),proteinuria(7.1%),respectively. [Conclusions] Apatinib is active for the treatment of advanced refractory soft tissue sarcomas with a manageable tolerability profile. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |